Close menu

September 10th, 2021 | 12:43 CEST

NanoRepro, XPhyto Therapeutics, BioNTech, Valneva - The next biotech wave is rolling!

  • Biotechnology
Photo credits:

So far, vaccine manufacturers can maintain their high valuation because the next wave of new infections is rolling in. In Germany, tests will be subject to fees starting in October, making public life more expensive for those who want to participate. In surveys, most German citizens have expressed support for fee-based testing; probably, the populations here should be separated into "vaccinated" and "unvaccinated" to indicate general opinion accurately. Four interesting values benefit from the current situation.

time to read: 4 minutes | Author: André Will-Laudien
ISIN: NANOREPRO AG | DE0006577109 , XPHYTO THERAPEUTICS | CA98421R1055 , BIONTECH SE SPON. ADRS 1 | US09075V1026 , VALNEVA SE EO -_15 | FR0004056851

Table of contents:

    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview


    NanoRepro - Into the next wave with partner Viromed

    NanoRepro was already able to benefit strongly from the demand for tests in 2021. Now a consortium of investors seems to be positioning itself. NanoRepro's partner, the Viromed Group, recently took a minority stake in the Marburg-based Company. Arguably, this is the first step toward putting NanoRepro's high cash reserves to good use.

    Viromed's plans go further, however, as it subsequently became known that it intends to acquire a majority stake in NanoRepro through various contributions in kind. However, Viromed did not yet provide details on the plans. According to the latest data, the Viromed Group currently holds less than 30% of NanoRepro.

    Viromed is a high-growth partner from the environment of hospital operators and significantly expands the spectrum of NanoRepro. That brings renewed fantasy for the NanoRepro share. The share price recently rose to EUR 11.50 and is currently consolidating at the EUR 9 mark. In the medium term, there should be a significant appreciation here!

    XPhyto Therapeutics - Sales launch for the new 25-minute test

    XPhyto Therapeutics is making good progress with its PCR tests. The recently announced launch of its 25-minute COVID-19 PCR test "COVID-ID Lab" was successful. During the pilot project at the test centers in Berlin, the workflows and protocols for the rapid, efficient, and reliable COVID-ID Lab were optimized for deployment. These technical and operational insights are critical for the product launch and further sales to existing and new customers. Now the stage is set for large-scale commercialization.

    "We are extremely pleased with the results of the pilot project. The practical lessons learned, from training protocols to efficient workflows, are necessary to accelerate the growth of our sales force. These results demonstrate the success of our business strategy in rapid point-of-care diagnostics," said Wolfgang Probst (COO). In parallel to the pilot project, concepts and services are being developed with partners to offer modular testing and hygiene solutions for larger events such as concerts, sporting events and conferences. Regarding the discussion about applying the 3G or 2G rule, this comes just at the right time because, in Baden-Württemberg, public events can only be attended with an up-to-date PCR test. XPhyto is here to help with its cost-effective 25min test, as other authorities and governments will also make the switch from antigen to PCR testing in the coming months. XPhyto's partner in this business is BeoVita GmbH & Co. KG.

    XPhyto's timing for the late summer sales launch could not be better. Recently, the share has consolidated somewhat and, at CAD 1.60, is now in a very interesting buy zone from a chart perspective. It is also being traded in Germany with good turnover. A medium-term entry is worthwhile in the EUR 1.05 to 1.25 range - because the Company's pipeline is full to bursting.

    BioNTech - Booster vaccines ensure high order intake

    According to experts, the availability of Corona vaccines continues to increase significantly. By the end of 2021, 12 billion doses will have been produced. Developers are coming from a wide variety of continents. Chinese vaccines account for around half of this, with Western manufacturers producing the other half. Every third person on earth is completely vaccinated against the coronavirus.

    There are even surpluses of vaccines at the moment because governments want to be ready for the potential mutants in the fall and offer booster vaccinations. The US, Canada, the EU and the UK will have so many vaccine doses at the end of September that they could give about 500 million doses to other countries without further damage to their vaccination campaigns. In 2022, Pfizer CEO Albert Bourla expects production to increase further to four billion doses of the Comirnaty vaccine. A large portion is already being supplied to poorer countries, and there is also sufficient market supply for 2022. Currently, however, demand for vaccination is low due to a lack of government action.

    BioNTech shares are still floating on top of the wave, even if the price has given up 28% from the August high. The price-to-sales ratio is about 6, and the P/E ratio in 2021 is 8.5. The ratios are now attractive again, so in weakness, one should get in.

    Valneva - New ideas from France

    The share of the French-Austrian biotech Company Valneva SE has almost doubled on a monthly basis. The background is the growing hope that the Company's Corona vaccine will receive approval before the end of this year. Perhaps too late, many investors are asking?

    The vaccine peak is likely to be passed in the fall, and companies like BioNTtech and Moderna have already sold their wares. But this view may fall short in the case of Valneva. Their vaccine, which is currently being tested in a phase 3 trial in the UK, is the only one in Europe based on the classical method of dead viruses. Just as has been the case for years with vaccinations against influenza or hepatitis, it could become a big hit. It could win over people who have not yet been vaccinated because of their skepticism about the new mRNA vaccines.

    So there is a lot of speculation, but also plenty of imagination in the share. Since the summer of 2020, the share price has risen by 325%. That means that a lot of hope is already priced in. However, anyone looking for diversification from the well-known names is in good hands with Valneva. From a chart perspective, the value must first rise above EUR 25 again, and then it could continue to run.

    The stocks considered here are active in the environment of pandemic control. Vaccine manufacturers have been in demand for months and are now consolidating strongly. Test providers such as NanoRepro or XPhyto could experience a decent renaissance in the fall.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.

    Der Autor

    André Will-Laudien

    Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

    About the author

    Related comments:

    Commented by Stefan Feulner on April 16th, 2024 | 07:40 CEST

    Formycon, Defence Therapeutics, Morphosys - Significant movement in the biotech sector

    • Biotechnology
    • Pharma
    • Cancer

    At the moment, investors are focusing on gold and Bitcoin in addition to the most important indices, like the DAX and Dow Jones. Meanwhile, the biotechnology sector is barely mentioned in the local newspapers. However, the market is on the move, and the wave of takeovers continues unabated. Recently, the Danish pharmaceutical company Genmab announced it was acquiring the private biotech company ProfoundBio for USD 1.8 billion in cash. The acquisition is intended to help deepen the cancer pipeline with next-generation antibody-drug conjugate therapies. Big Pharma is likely to make further acquisitions in this area in the near future.


    Commented by Juliane Zielonka on April 12th, 2024 | 07:00 CEST

    AI in healthcare with Evotec, Defence Therapeutics, Bayer: Revolutionary advances and medical breakthroughs

    • Biotechnology
    • Pharma
    • AI

    Artificial intelligence (AI) is gaining momentum in the healthcare sector. AI-based systems can use medical databases to save valuable time in research, enabling companies like Defence Therapeutics to go to market faster than others. In oncology research, the Canadian company has just achieved a breakthrough that gives hope to many cancer patients. AI-assisted diagnoses allow diseases to be detected earlier and treated more effectively, leading to improved quality of life for patients. Precision medicine in strong partnership networks is Evotec's focus. The share is particularly popular with hedge fund managers. Analyzing medical images and data in real-time and detecting even the smallest deviations or anomalies is the top priority for Bayer AG in collaboration with Google Cloud. Which companies are convincing investors the most?


    Commented by Fabian Lorenz on April 10th, 2024 | 07:00 CEST

    BASF and Cardiol Therapeutics recommended to buy! TUI share with momentum!

    • Biotechnology
    • Cancer
    • travel
    • chemicals

    BASF shares have gained over 30% within six months. But is the rally in BASF shares slowly running out of steam? The fact that the share did not rise sharply yesterday despite a significant price target increase suggests this is the case. Many experts see little potential for further price increases. The situation is different for the biotech company Cardiol Therapeutics. The analysts at Canaccord believe that the shares of the specialist in cardiovascular diseases could perform by around 200%. Financing is secured until 2026, and important study data is due in the current quarter. The TUI share has been on a roll for several months now. Will the share continue to rise with the increase in temperatures? Management is certainly optimistic about the future.